Immunohistochemical as well as genome wide analysis on patient material have shown that GRP78 is overexpressed in several tumors refractory to therapy like glioma (Pyrko et al., 2007), leukemia (Uckun et al., 2011), prostate (Daneshmand et al., 2007), and breast cancer (Scriven et al., 2009). Here, HSPA5 is linked to breast cancer.